MRTX 1719
Alternative Names: MRTX-1719Latest Information Update: 22 Jun 2024
At a glance
- Originator Mirati Therapeutics
- Class Antineoplastics
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Mesothelioma; Neurilemmoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical study in pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Apr 2024 Updated pharmacodynamics data from a preclinical trial in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)